MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ortiz de Montellano, P. R.
Right arrow Articles by Langry, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ortiz de Montellano, P. R.
Right arrow Articles by Langry, K. C.

The allylisopropylacetamide and novonal prosthetic heme adducts

PR Ortiz de Montellano, RA Stearns and KC Langry

Administration of 2-isopropyl-4-pentenamide (AIA) and 2,2-diethyl-4- pentenamide (novonal) to phenobarbital-pretreated rats gives rise to abnormal porphyrins derived from the prosthetic heme group of inactivated cytochrome P-450. The abnormal porphyrins, identified by NMR and other spectroscopic methods, are N-alkylated protoporphyrin IX derivatives in which the N-alkyl moiety is derived from the parent drug by addition of a hydroxyl group to the internal carbon and of a porphyrin nitrogen to the terminal carbon of the pi-bond. A secondary reaction of the hydroxyl with the amide group converts the N-alkyl moiety into a lactone. The indicated alkylation-lactonization sequence is supported by the fact that the AIA adduct formed under an atmosphere of 18O2 incorporates one labeled oxygen atom. The regiochemistry of heme alkylation is consistent with a previously postulated active site topology [J. Biol. Chem. 258:4202-4207 (1983)].

Volume 25, Issue 2, pp. 310-317, 03/01/1984
Copyright © 1984 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
J. A. Lavigne, K. Nakatsu, and G. S. Marks
Identification of Human Hepatic Cytochrome P450 Sources of N-alkylprotoporphyrin IX after Interaction with Porphyrinogenic Xenobiotics, Implications for Detection of Xenobiotic-Induced Porphyria in Humans
Drug Metab. Dispos., July 1, 2002; 30(7): 788 - 794.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
P.-G. Forkert, P. D. Premdas, and R. J. Bowers
Epoxide Formation from Diallyl Sulfone Is Associated with CYP2E1 Inactivation in Murine and Human Lungs
Am. J. Respir. Cell Mol. Biol., November 1, 2000; 23(5): 687 - 695.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. D. Premdas, R. J. Bowers, and P.-G. Forkert
Inactivation of Hepatic CYP2E1 by an Epoxide of Diallyl Sulfone
J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 1112 - 1120.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1984 by the American Society for Pharmacology and Experimental Therapeutics